TY - JOUR
T1 - Recent advances in gut Microbiota mediated therapeutic targets in inflammatory bowel diseases
T2 - Emerging modalities for future pharmacological implications
AU - Shamoon, Muhammad
AU - Martin, Natalia M.
AU - O'Brien, Claire L.
N1 - Funding Information:
MS is grateful to COB who assisted with throughout preparation of the review article. COB acknowledges NHMRC Peter Doherty Fellowship.
Publisher Copyright:
© 2019
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2019/10
Y1 - 2019/10
N2 - The inflammatory bowel diseases (IBDs) are chronic inflammatory conditions, which are increasing in prevalence worldwide. The IBDs are thought to result from an aberrant immune response to gut microbes in genetically susceptible individuals. Dysbiosis of the gut microbiome, both functional and compositional, promotes patient susceptibility to colonization by pathobionts. Manipulating gut microbial communities and gut microbiota-immune system interactions to restore gut homeostasis or reduce inflammation are appealing therapeutic models. We discuss the therapeutic potential of precision microbiota editing, natural and engineered probiotics, the use of gut microbiota-derived metabolites in colitogenic phenotypes, and intestinal stem cells, in maintaining gut microbiota balance, restoring the mucosal barrier, and having positive immunomodulatory effects in experimental IBD. This review highlights that we are only just beginning to understand the complexity of the microbiota and how it can be manipulated for health benefits, including treatment and prevention of the clinical IBDs in future.
AB - The inflammatory bowel diseases (IBDs) are chronic inflammatory conditions, which are increasing in prevalence worldwide. The IBDs are thought to result from an aberrant immune response to gut microbes in genetically susceptible individuals. Dysbiosis of the gut microbiome, both functional and compositional, promotes patient susceptibility to colonization by pathobionts. Manipulating gut microbial communities and gut microbiota-immune system interactions to restore gut homeostasis or reduce inflammation are appealing therapeutic models. We discuss the therapeutic potential of precision microbiota editing, natural and engineered probiotics, the use of gut microbiota-derived metabolites in colitogenic phenotypes, and intestinal stem cells, in maintaining gut microbiota balance, restoring the mucosal barrier, and having positive immunomodulatory effects in experimental IBD. This review highlights that we are only just beginning to understand the complexity of the microbiota and how it can be manipulated for health benefits, including treatment and prevention of the clinical IBDs in future.
KW - Gut microbiota
KW - Inflammatory bowel disease
KW - Intestinal stem cells
KW - Microbial metabolites
KW - Precision edited microbiome
KW - Probiotics
KW - Therapeutics
UR - http://www.scopus.com/inward/record.url?scp=85070958970&partnerID=8YFLogxK
U2 - 10.1016/j.phrs.2019.104344
DO - 10.1016/j.phrs.2019.104344
M3 - Review article
C2 - 31400403
AN - SCOPUS:85070958970
SN - 1043-6618
VL - 148
SP - 1
EP - 12
JO - Pharmacological Research
JF - Pharmacological Research
M1 - 104344
ER -